Pill for Obstructive Sleep Apnea Shows Potential
New research has shown that a pill called AD109 may provide a more convenient treatment option for obstructive sleep apnea (OSA). In a study involving 646 participants, those taking AD109 experienced significant reductions in apnea-hypopnea index scores compared to those on a placebo. If approved by the FDA, this medication could offer an alternative to cumbersome existing treatments like continuous positive airway pressure devices.
- ▪AD109 is a fixed-dose pill that combines atomoxetine and aroxybutynin.
- ▪Participants taking AD109 showed a median reduction of 6.5 fewer apnea events per hour compared to 1.4 fewer events with placebo.
- ▪The study found a 70% reduction in loud snoring among those treated with AD109.
Opening excerpt (first ~120 words) tap to expand
ORLANDO, Fla. — New research is giving people with obstructive sleep apnea (OSA) a reason to hope for a more convenient treatment: a pill that improved upper airway muscle dysfunction and reduced apnea-hypopnea index (AHI) scores among 324 people taking AD109 vs 322 taking a placebo for 6 months.OSA can be highly inconvenient for people struggling to get a healthy night’s sleep, affecting quality of life for them and their sleep partners. Also, existing treatments like continuous positive airway pressure devices can be cumbersome and difficult for some patients to accept and adhere to over the long term.An oral treatment could improve these challenges.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
